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ABSTRACT: Induced pluripotent stem cells have great potential as a human model system in regenerative medicine, disease mod-
eling and drug screening. However, their use in medical research is hampered by laborious reprogramming procedures that yield 
low numbers of induced pluripotent stem cells. For further applications in research, only the best, competent clones should be used. 
The standard assays for pluripotency are based on genomic approaches, which take up to 1 week to perform and incur significant 
cost. Therefore, there is a need for a rapid and cost-effective assay able to distinguish between pluripotent and non-pluripotent cells. 
Here, we describe a novel multiplexed, high-throughput and sensitive peptide-based multiple reaction monitoring mass spectrome-
try assay, allowing for the identification and absolute quantitation of multiple core transcription factors and pluripotency markers. 
This assay provides simpler and high-throughput classification into either pluripotent or non-pluripotent cells in 7-minutes analysis 
while being more cost-effective than conventional genomic tests. 
Induced pluripotent stem cells (iPSCs) are somatic cells, 
which are reprogrammed to the pluripotent state and acquire 
properties comparable to embryonic stem (ES) cells (1). Ini-
tially generated from human dermal fibroblasts by retroviral 
transfection of four transcription factors OCT4, SOX-2, c-
MYC and KLF-4 (2), iPSCs can be now obtained by numer-
ous different strategies, such as plasmids (3), non-integrating 
viruses (Sendai virus) (4, 5), drug-inducible systems (6), 
transposition (7), protein transduction (8) or mature mi-
croRNAs (9). Despite multiple reprograming techniques avail-
able this process remains time-consuming and relatively inef-
ficient. For further applications in research, only the best, 
competent clones need to be selected and used. The quality 
control assays vary from unreliable visualization of colony-
morphology using light microscopy or extracellular marker 
staining, through more sophisticated embryoid body or tera-
toma formation. The latter in vivo test is not only time-
consuming and expensive, but also lacks the standardization 
and raises ethical concerns (10). Therefore the current trend is 
to move towards assays based on gene expression, i.e. Plu-
riTest (11) or ScoreCard (12). However these tests require 
isolation of genetic material prior to analysis, take up to 1 
week to perform and incur significant cost. 
In order to increase the simplicity and efficiency of iPSCs 
characterization, we have developed a multiplexed peptide 
based multiple reaction monitoring - mass spectrometry assay 
(MRM-LC-MS/MS), enabling quantitation of 15 pluripotency 
markers in just 7 minutes. This test provides a simple and 
high-throughput measurement of pluripotency signature using 
as little as 200,000 cells. This work describes the development 
of a novel targeted proteomic assay and comparison of the 
mass spectrometry-based test with conventionally used tests 
based on gene expression profiles (ScoreCard and PluriTest). 
 
EXPERIMENTAL PROCEDURES 
Cell lines and culture. Cell lines used in this study are 
listed in Table S-1. iPSC lines (prefixed with SFC) were de-
rived as part of the EU IMI-funded programme, StemBANCC, 
from donors who had given signed informed consent for deri-
vation of hiPSC lines from skin biopsies. The SFC826 lines 
were derived from SF826 donor fibroblasts collected by the 
University of Lübeck. The study was approved by the ethics 
committee of the University of Lübeck, and all participants 
gave written informed consent prior to their participation in 
the study. SBAD iPSC lines were derived and characterised at 
the University of Newcastle from Lonza fibroblasts CC-2511, 
Lot 264781, Tissue Acquisition number 23447. All other 
StemBANCC iPSC lines were derived and characterised at the 
University of Oxford, James Martin Stem Cell Facility.  The 
human ES cell line HUES-2 (passages 16–38) was obtained 
from the HUES Facility, Harvard University.  Ethical approval 
for work on all hES cell lines was reviewed and approved by 
the UK Stem Cell Bank Steering Committee (Medical Re-
search Council, London UK, 20.10.2005), and work using this 
 line was funded by the Oxford Martin School and the Well-
come Trust. 
For derivation of iPSC lines, skin biopsies were cultured as 
previously described (13) to promote outgrowth of fibroblasts, 
in ADMEM (Invitrogen) supplemented with USDA-approved 
foetal bovine serum (10%; Sigma) and penicillin/streptomycin 
(1%) in a humidified incubator (37 °C, 5% CO2). Fibroblasts 
were reprogrammed at passage 3-5, using Cytotune Sendai 
virus reprogramming kit (Invitrogen) according to the manu-
facturer’s instructions (scaled down to 50,000 fibroblasts).  
Transduced fibroblasts were seeded onto CF1 outbred mouse 
embryonic feeder cells (MEF, Merck) on 0.1% gelatin coated 
plates (Sigma) on day 7, and cultured in KnockOut serum 
replacement medium (Knock-out DMEM (Invitrogen), KO-
Serum Replacement (20% Invitrogen), Glutamax-I (2 mM 
Invitrogen), non-essential amino acids (1%, Invitrogen), peni-
cillin (100 U/mL Invitrogen), streptomycin (100 µg/mL Invi-
trogen), 2-ME (55 µM Invitrogen) and bFGF (10 ng/mL 
R&D), substituting with MEF-conditioned medium from day 
10 onwards.  Colonies displaying iPSC morphology were 
picked and passaged on MEFs by manual dissection every 5-7 
days. iPSC lines were adapted to feeder-free culture conditions 
in mTeSR™1 (StemCell Technologies), on Matrigel coated 
plates (BD Matrigel hESC-qualified Matrix), passaging as 
clumps using 0.5 mM EDTA in PBS (Beers et al., 2012).  
Cells were frozen in SNP-QCed batches at p15-25 and used 
for experiments within a minimal number of passages post-
thaw to ensure consistency. 
iPSC lines that have not been previously published are char-
acterised in Figure S-1.  
Initial assessment of pluripotent markers used antibodies to 
TRA-1-60 (B119983, IgM-488, Biolegend) and Nanog 
(2985S, IgG-647, Cell Signaling), with appropriate isotype 
control, at the same concentration, from the same supplier. 
Cells were fixed for 10 minutes in 2% paraformaldehyde in 
PBS (Alfa Aesar), permeabilised in 100% methanol at -20 °C 
for at least 30 min before staining. Fluorescence was measured 
using a FACS Calibur (Becton Dickinson), and data analysed 
with FlowJo software.  
RT-PCR was used to assess clearance of Cytotune Sendai 
virus-delivered reprogramming genes. RNA was isolated us-
ing an All-Prep kit (Qiagen) and reverse transcribed using a 
RetroScript kit (Ambion), with 2 µg template RNA in a 20 µL 
reaction. 2 µl of 1:10 dilution of cDNA product was used in a 
25 µl RT-PCR reaction, performed according to the manufac-
turer’s instructions and run on a 1.5% agarose gel with Log2 
ladder (NEB). Positive controls (fibroblasts infected 5 days 
previously) were always run in parallel. Primers were SeV F: 
GGATCACTAGGTGATATCGAGC, R: 
ACCAGACAAGAGTTTAAGAGATATGTATC 181bp; 
SOX2 F: ATGCACCGCTACGACGTGAGCGC, R: 
AATGTATCGAAGGTGCTCAA 451bp; KLF4 F: 
TTCCTGCATGCCAGAGGAGCCC, R: 
AATGTATCGAAGGTGCTCAA 410bp; c-MYC F: 
TAACTGACTAGCAGGCTTGTCG, R: 
TCCACATACAGTCCTGGATGATGATG 532bp; OCT4 F: 
CCCGAAAGAGAAAGCGAACCAG, R: 
AATGTATCGAAGGTGCTCAA 483bp; β-Actin control 
Eurogentec 92bp.  
Genomic DNA was made using an All-Prep kit (Qiagen). 
Genome integrity was assessed by Illumina Human CytoSNP-
12v2.1 beadchip array (~300,000 markers) or OmniExpress24 
array (700,000 markers) and analysed using GenomeStudio 
software (Illumina). Ancestry plots (a tracking QC to confirm 
that the iPSC lines derive from the parental fibroblasts) and 
karyograms were generated using a customised SNP analysis 
pipeline in StemDB, which hosts StemBANCC datasets 
(https://www.stemdb.org). 
iPSCs used for the blind test were grown in feeder free con-
ditions in Essential 8 medium (ThermoFisher) on Matrigel 
coated plates (BD Matrigel hESC-qualified Matrix). Cells 
were harvested using 0.5 mM EDTA in PBS, centrifuged, and 
the resulting pellets were taken for analysis. Three different 
fibroblast lines were cultured in DMEM (Sigma) containing 
10% fetal calf serum, 2 mM L-glutamine, and non-essential 
amino acids. Fibroblasts were harvested with 0.05% trypsin-
EDTA, centrifuged, and the resulting pellets were taken for 
analysis. The collected cell pellets were labeled 1-7 so that the 
person performing the test was unaware of the cell type of 
each sample.  
Differentiation to embryoid bodies. iPSC were cultured as 
above, and set up for both harvesting and differentiation. Har-
vesting was by washing with PBS, incubating for 5 mins with 
TrypLE express (Life Tech), then diluted 1/10 in PBS, centri-
fuged at 400g for 5 minutes, supernatant aspirated and the 
pellet frozen immediately at -80 °C. Cells were pelleted at ~2 
million cells/pellet, 3 pellets per sample: 1 pellet for prote-
omics, 2 for RNA. For differentiation cultures, 10,000 PSC 
were seeded per Aggrewell 800 as per manufacturer's protocol 
(StemCell Technologies). Seeding was in mTeSR with 10 µm 
Rock inhibitor Y-27632 (AbCAM), then medium changed at 
24h into ScoreCard differentiation medium as per ScoreCard 
manufacturer's protocol (Life Technologies), fed daily and 
harvested at day 4. For 14 day EBs, d4 Aggewell EBs were 
plated to matrigel as per ScoreCard protocol, and fed every 2d 
with ScoreCard medium for 10d (undirected differentiation).  
Targeted proteomics: MRM-based triple quadrupole 
mass spectrometry. All materials were of analytical and 
mass-spectrometry grade. DL-dithiothreitol (DTT), iodoa-
cetamide, ASB-14, Tris base and urea were all purchased from 
Sigma-Aldrich. UPLC-MS grade acetonitrile (ACN), formic 
acid (FA) and water were obtained from Fluka, and sequenc-
ing-grade modified porcine trypsin from Promega. All buffers 
and solutions were prepared using ultra-pure 18 MΩ water 
(MilliQ) and UPLC solvents using UPLC-MS grade water. 
Potential pluripotency biomarkers were determined from the 
literature and current pluripotency tests (staining markers and 
self-renewal markers included in ScoreCard assay). Repre-
sentative quantotypic peptides for each protein were selected 
using the open source online global proteome machine MRM 
database at www.thegpm.org (14) and SRM atlas database at 
www.srmatlas.org (15). Custom synthesised standard peptides 
(Genscript, USA) were used to create the transitions list, opti-
mize the peptide detection and determine the retention time. 
Details of confirmed marker peptides are given in Table S-2. 
Harvested cell pellets (~2 million cells/pellet) were dis-
solved in lysis buffer containing 100mM Tris HCl, 6M Urea, 
2M Thiourea, 2% ASB-14, and spiked with 20 pmol of stable 
isotope labelled (SIL) analog of standard peptides with trypsin 
tag (Thermo-Scientific) in order to monitor the efficiency of 
digestion. Subsequently cell lysates were digested using the 
sequencing-grade trypsin as described previously (16), and 
purified using C18 Isolute 96-well plate (Biotage) according to 
the manufacturer’s instructions. Eluted peptides were freeze-
dried and resuspended in 100 µL of 0.1% formic acid in water. 
10 µL of sample was loaded onto a Waters CORTECS UPLC 
 C18 Column, 90 Å, 1.6 µm, 2.1 mm x 50 mm attached to a 
C18 VanGuard pre-column. UPLC-MS/MS analysis was per-
formed on a Acquity UPLC system (Waters) coupled to a 
XevoTM TQ-S triple quadrupole mass spectrometer (Waters) 
equipped with electrospray source operating in positive ioniza-
tion mode as described previously (16). Analytical UPLC 
chromatography was performed using the flow rate 0.8 
mL/min, and a 7-min linear gradient starting at 100% solvent 
A (0.1% formic acid in water), ramping to 40% solvent B 
(0.1% formic acid in acetonitrile) in 3.5 min, then to 99.9% 
Solvent B over 0.25 min (held for 1.5 min) and finally de-
creased to 100% solvent A in 0.25 min and reconditioned for 
1.5 min. Dynamic Multiple Reaction Monitoring of a multi-
plex of 15 markers (at least two peptides per protein and two 
transitions per peptide were monitored- one for quantitation 
and one for confirmation) was performed over a 7 min gradi-
ent with a dwell time set up to automatic, and minimum 8 data 
points per peak. Only one NANOG peptide was monitored, 
due to the primary sequence of this protein, characterized by 
low number of tryptic sites and multiple phosphorylation sites, 
decreasing number of possible candidate peptides, which 
could be used in the assay. Additionally, only one transition of 
TRIM6 peptide VIPMTLRR was monitored due to the large 
number of non-specific transitions generated during method 
development. Chromatograms were analysed using Waters 
TargetLynx Software V.4.1. Standard peptides were dissolved 
in lysis buffer, spiked with SIL standard peptides, digested and 
purified using C18 Isolute 96-well plate (Biotage) in the same 
manner as cell pellets to encounter matrix effect on peptide 
retention time. Eluted standard peptides were freeze-dried and 
resuspended in 0.1% formic acid in water  to concentrations 
used in standard curve.  
Peptides were standardised by using a spiked SIL peptide 
and absolute levels were obtained from standard curves. A 
standard curve of 0-1 pmol/µL of each peptide was exported to 
Excel and GraphPad Prism for statistical analysis. The lineari-
ty of R2 > 0.90 was achieved for all calibration curves, except 
the Podocalyxin, for which R2=0.87 was achieved (Figure S-
2). Limit of quantitation (LOQ) was determined for each com-
pound using 5 repeat measurements for 5 consecutive days of 
standard peptides. LOQ defined as the compound concentra-
tion for which calculated coefficient of variation (CV) was 
below 20%, was found to be 50 fmol/µL for PODXL and 
GAPDH, 10 fmol/µL for LIN28 and 5 fmol/µL for SOX-2, 
OCT4 and CD44. The intra-batch variation was determined to 
be between 0.4 and 15%, and inter-batch variation being be-
tween 1.28 and 19.5% (n=5 for 5 consecutive days).  
Transcriptomic profiling. RNA extraction was done using 
RNeasy mini kit (Qiagen). Out of the total RNA yield collect-
ed, 1µg was used for microarray profiling. Genomewide anal-
ysis of gene expression was done using Illumina’s Human-
HT-12-v4 expression BeadChip according to Illumina’s proto-
col. Pluripotency assessment was performed using PluriTest 
algorithm (11) (pluritest.org). When available, the leftover 
RNA was profiled by multiplex qPCR profiling, using Taq-
man(®) hPSC  ScoreCard™ panel (17) (Thermofisher Scien-
tific) for pluripotency and differentiation assessment according 
to the manufacturer’s protocol. 
Data analysis. All data analyses were carried out in R. Re-
sults presented in this study can be reproduced by the Rmark-
down script available from 
http://wwwfgu.anat.ox.ac.uk/downloads/compbio_projects/C
W025_WESSELY_MRM/ 
 Samples used in the PluriTest and ScoreCard assay are 
listed in Table S-3. PluriTest classification results and scores 
were obtained from the analysis pipeline implemented as a 
web-service and available from http://www.pluritest.org/ (ac-
cessed October 2015). Raw data from five Illumina Hu-
manHT-12 V4.0 expression beadchips each containing 12 
samples were individually uploaded in form of .idat files. The 
five corresponding results tables were downloaded and 
merged to obtain PluriTest results for 49 samples (remaining 
11 samples not part of this study). 
Normalised probe expression levels of selected genes of in-
terest, which were used to compare measurements between the 
three assays, were obtained from probe expression profiles 
generated with GenomeStudio version 1.9.0. Data was pre-
processed in the same way as the standardised PluriTest web-
service by using the lumi R package (18, 19) with variance 
stabilising transformation (VST) followed by robust spline 
normalisation (RSN). Gene annotation of microarray probes 
was based on GenomeStudio mapping. If several probes 
mapped to the same gene, the probe with the highest 
Spearman's correlation coefficient with proteomic MRM assay 
levels was chosen. 
ScoreCard qPCR assay results were received from Life-
Tech/ThermoFisher for a total of 42 samples. Scores and clas-
sification of samples as positive, negative or borderline for 
self-renewal potential were extracted from the report. Fold 
changes of self-renewal genes also analysed by the MRM as-
say (OCT4/POU5F1 and SOX-2) were used as provided in the 
report. CD44, used as a negative control for mouse contamina-
tion in the qPCR assay, was expectedly not detected in any 
sample (CT values = 40). 
 
RESULTS AND DISCUSSION 
Reprogrammed cell lines. A total of 14 newly repro-
grammed cell lines (3 clones each from 5 donors, except for 
one donor with 2 clones) and an established human embryonic 
stem cell line HUES-2 (20) at three stages of differentiation: 
iPSCs (undifferentiated), 4-day and 14-day embryoid body 
(EB) formation were included in the study. Additionally, the 
donor fibroblast cell lines were used as negative control (Table 
S-1 and Figure S-1). Cell lines included in the study carried 
different mutations related with Parkinson’s disease: PTEN-
induced putative kinase 1 (PINK1) mutation, A53T mutation 
in α-synuclein, triplication in the α-synuclein gene (SNCA), 
and the N370S mutation at the acid beta-glucosidase (GBA) 
gene, which is associated with Gaucher disease (Table S-1). 
The differentiation potential of the reprogrammed cell lines 
was confirmed by the observed trends of increasing germ-
layer scores when iPSCs were compared to 4-day and 14-day 
embryoid bodies, although not all samples at the embryoid 
body stage were classified as positive for specific germ layers 
(Figure S-3). Differentiation potential was found to be most 
pronounced for mesoderm layer and least pronounced for en-
doderm layer.  The trends for differentiation potential ob-
served here largely correspond to the pattern previously ob-
served: rapid activation of ectoderm markers, gradual activa-
tion of mesoderm markers and delayed activation of endoderm 
markers (17). 
Development of MRM-based pluripotency signature as-
say. We primarily included the core transcription factors (TFs) 
as candidate biomarkers: OCT4, SOX-2, KLF4 and c-MYC in 
the MRM-based assay, and subsequently added other factors 
qualified in PluriTest and ScoreCard assays as pluripotency- 
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Figure 1. Schematic representation of a targeted proteomic mass spectrometry test for pluripotency. (A) The workflow of the assay: a cell 
pellet is spiked with SIL standard peptides, trypsin digested, desalted and concentrated. Resulting peptides are then separated by UPLC and 
analysed by a triple quadrupole mass spectrometer. (B) Typical and representative result of a sample analysis. The overlaid chromatogram 
of the standard peptides included in the multiplexed targeted proteomic assay and detected in cell lysates of iPSc and fibroblasts. Only 5 
markers used for quantitation are displayed. 
associated markers (12, 21). The final assay was developed for 
identifying and quantitating Myc proto-oncogene (c-MYC), 
Kruppel-like factor 4 (KLF4), Transcription Factor SOX-2, 
POU domain transcription factor 1 (OCT4, also known as 
POU5F1), Homeobox protein NANOG, Protein LIN28 homo-
log A, Zinc finger protein 42 (REX1), Tripartite motif-
containing protein 6 (TRIM6), Steroid hormone receptor 
ERR2 (ESRRB) and Zinc finger protein GLIS1. Additionally, 
histochemical pluripotency markers: Podocalyxin (PODXL- 
transmembrane glycoprotein shown to have binding activities 
with TRA-1-60 and TRA-1-81 (22)), Alkaline Phosphatase, 
Neural cell adhesion molecule 1 (CD56), CD44 antigen and a 
housekeeping protein- glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) were added to the multiplexed MRM panel. 
For each marker, we selected at least two proteotypic peptides, 
determined two optimum MRM transitions (pairs of parent 
and product ion) and instrument parameters (Table S-2). These 
15 candidate pluripotency biomarkers were multiplexed into a 
7-minute targeted peptide MRM-based assay (Figure 1). 
Analysis of reprogrammed cell lines by MRM-based as-
say. The targeted proteomic analyses of reprogrammed cell 
lines, fibroblasts and human embryonic stem cell lines re-
vealed that the four biomarkers OCT4, SOX-2, LIN28 and 
PODXL allowed for the measurement of a pluripotency signa-
ture. The mean concentration of these markers normalised to 
GAPDH, are significantly different between fibroblasts and 
iPSCs (p < 0.0005, Wilcoxon rank sum test) and allowed for 
clear classification of a given cell line into one of these groups 
(Table 1 and Figure 2C). The accuracy of using GAPDH for 
normalization was confirmed by parallel normalization with 
two other housekeeping proteins: DNA replication licensing 
factor MCM2 and DNA mismatch repair protein MSH2 (data 
not shown). No significant difference was observed and thus 
we retained the normalization to GAPDH, being the standard 
protein to normalise against in biochemistry. Another normali-
zation method, such as the quantitative protein assay could not 
be performed due to the high concentration of urea and thiou-
rea in the lysis buffer, being incompatible with the assay. 
The pluripotency signature was also confirmed by quantitat-
ing the negative marker, CD44, a surface glycoprotein, which 
functions as a receptor for hyaluronic acid and was reported 
previously as highly expressed in human fibroblasts and ab-
sent in pluripotent cells (23). The concentration of CD44 
measured by proteomic assay in fibroblasts was almost 95-fold 
higher than in iPSCs. Augmenting this marker into our MRM 
assay allows for identification of non-fully reprogrammed 
clones, which still express fibroblast surface markers.  
The principal components analysis based on OCT4, SOX-2, 
LIN28, PODXL and CD44 markers (Figure 2A) clearly shows 
the separation of fibroblasts from the rest of the samples and 
highlights the transition from undifferentiated cells to 14 day 
EBs. No significant difference in expression of c-MYC marker 
was found between fibroblasts and iPSCs lines. In line with 
our results, c-MYC was shown to be expressed strongly in 
pre-iPS cells (24). However, the remaining candidate bi-
omarkers included in the assay (KLF4, NANOG, REX1, 
TRIM6, ESRRB, GLIS1, Alkaline Phosphatase and CD56) 
were largely not detected in the samples. The reason for the 
absence of these potential biomarkers is unclear but it is well 
documented that there is a poor relationship between mRNA 
and protein content of the cell (25). Another possible reason is 
that the abundance levels of those proteins cannot be detected 
by this method. However, the detected OCT4, SOX-2, LIN28, 
PODXL and CD44 demonstrate sufficient potential for use in 
clearly discriminating fibroblasts from iPSCs. Therefore the 
lack of detection of these other markers is not needed for the 
purpose of this assay. 
Analysis of reprogrammed cell lines by ScoreCard and 
PluriTest. Technical replicates of reprogrammed cell lines 
submitted to the MRM pluripotency assay were also analysed 
using the commercially available TaqMan® hPSC Score-
Card™ Assay and the open-access bioinformatic assay Plu-
riTest. Both tests provide a number of scores that are used to 
 −3
−2
−1
0
1
−5.0 −2.5 0.0 2.5 5.0
PC1 (77.5 %)
P
C
2
 (
1
4
.1
 %
) Cell type
iPSC
4d
14d
fibro
ScoreCard PluriTest
13
2
55
1
10
2
4
14
1
5
10
2
9
4 4
0
5
10
15
iPSC 4d 14d fibro iPSC 4d 14d fibro
N
u
m
b
e
r 
o
f 
s
a
m
p
le
s
Result POS BOR NEG
OCT4 SOX2 LIN28 PODXL CD44
0
2
4
6
8
8
10
12
14
0.0
0.5
1.0
1.5
2.0
M
R
M
 a
s
s
a
y
lo
g
2
(y
 +
 1
)
P
lu
riT
e
s
t m
ic
ro
a
rra
y
p
ro
b
e
 e
x
p
re
s
s
io
n
S
c
o
re
C
a
rd
 q
P
C
R
fo
ld
 c
h
a
n
g
e
iPSC 4d 14d fibro iPSC 4d 14d fibro iPSC 4d 14d fibro iPSC 4d 14d fibro iPSC 4d 14d fibro
OCT4 SOX2 LIN28 PODXL CD44
0
2
4
6
8
0
2
4
6
8
S
c
o
re
C
a
rd
P
lu
riT
e
s
t
iPSC 4d 14d fibro iPSC 4d 14d fibro iPSC 4d 14d fibro iPSC 4d 14d fibro iPSC 4d 14d fibro
p
ro
te
o
m
ic
 l
e
v
e
l:
 l
o
g
2
(y
 +
 1
)
Gene expression assay result POS BOR NEG
A B
C
D
 
Figure 2. Results from proteomic and genomic pluripotency tests. (A) Principal components analysis (PCA) of proteomic MRM meas-
urements of five biomarkers (OCT4, SOX-2, LIN28, PODXL and CD44) from 52 samples (see Table S-1 for the sample list). The percent-
age of variance explained by the first and second principal components (PC1 and PC2) is shown in brackets. (B) ScoreCard’s self-renewal 
and PluriTest’s classification of samples from different cell types into three categories: positive (POS), negative (NEG) or borderline 
(BOR). See Table S-3 for genomic test results. (C) Boxplots of assay measurements from individual pluripotency tests for five biomarkers. 
Boxes represent inter-quartile ranges (IQR) with a horizontal line for the median, lower and upper whiskers extend to the lowest and high-
est value within 1.5 * IQR and measurements beyond the end of whiskers are plotted as points. The black points highlight the measure-
ments of the embryonic stem cell line HUES2. Seven and four fibroblast samples were analysed by the proteomic and genomic assays, 
respectively. The number of samples of other cell types is 15 in all three assays except for ScoreCard embryoid bodies (4d: n=11, 14d: 
n=12). (D) MRM measurements are shown as boxplots equivalent to the top row in c and compared to the genomic test results using the 
same colour code as in b. Samples not analysed by ScoreCard or PluriTest are shown in grey. Abbreviations: 4d- 4-day embryoid body; 
14d- 14-day embryoid body; y- fmol of biomarker/fmol of GAPDH. 
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Figure 3. Results of the MRM blind test. Measurements of five biomarkers allowing for the classification into either iPSC or fibroblast 
range. Blind 1, 2 and 6 were correctly classified as iPSC, Blind 3, 4 and 5 as fibroblast. Blind 7, expressing both iPSC and fibroblast mark-
ers, corresponds to the iPS cell line with spontaneous differentiation. As a comparison, boxplots are shown for MRM assay measurements 
of n=15 iPSC samples (including HUES2) and n=7 fibroblast samples. These boxplots are equivalent to the ones shown in Figure 2C. 
Blind samples are listed in Table S-4. Abbreviations: y, fmol of biomarker/fmol of GAPDH. 
Table 1. Concentration ranges of biomarkers OCT4, SOX-2, PODXL, LIN28 and CD44 in Fibroblasts and iPSc cells detect-
ed by targeted proteomic assay. 
 Fibroblast n=7 
(fmol of biomarker/ fmol of GAPDH) 
iPSC n=15 
(fmol of biomarker/ fmol of GAPDH) 
Biomarker Mean Median Min-Max Mean Median Min-Max 
OCT4 0.01 0.00 0-0.06 5.42 3.06 1.46-27.45 
SOX-2 0.002 0.00 0-0.02 1.71 1.08 0.33-7.27 
PODXL 2.17 2.35 0.07-3.73 60.89 34.97 16.98-260.87 
LIN28 0.01 0.00 0-0.1 18.04 16.75 6.15-34.36 
CD44 12.14 11.01 5.54-20.91 0.13 0.03 0-1.04 
 
classify samples as being positive or negative for self-renewal 
or borderline (PluriTest labels the latter samples as ‘further’). 
ScoreCard classified 86% of iPSCs lines as positive for self-
renewal potential, whereas the remaining samples were classi-
fied as borderline. 45% of 4d EBs and 17% of 14d EBs also 
showed self-renewal potential (Figure 2B and Table S-3). Plu-
riTest confirmed a pluripotency signature for 93% of iPSCs 
samples, including the two samples described as borderline by 
ScoreCard. The microarray-based test classified more EB 
samples positively than ScoreCard, including all the samples 
apart from one classified as pluripotent by ScoreCard (Figure 
2B and Table S-3). However, it should be noted that PluriTest 
is usually not used for embryoid body samples. Both genomic 
tests show a high correlation between pluripotency scores 
(Spearman’s correlation 0.8).  
Comparison of MRM-based test results with ScoreCard 
and PluriTest. Direct comparison of the targeted proteomic 
test and gene-based pluripotency tests can be challenging since 
previous reports have shown that in general, protein abun-
dances correlate with mRNA very poorly (26), which can be 
explained by translation and degradation of proteins occurring 
after transcription. Proteomic expression of the OCT4, SOX-2, 
LIN28, PODXL and CD44 biomarkers measured by the MRM 
assay were compared to corresponding gene expression data 
measured by the two genomic tests (Figure 2C). The genome-
wide microarray used by PluriTest includes all corresponding 
genes, whereas ScoreCard's qPCR assay includes only two of 
our selected set of biomarkers (OCT4 and SOX-2). The trends 
across the four different stages of cell differentiation observed 
by targeted proteomics were also found for gene expression 
measurements (Figure 2C). It is noteworthy that the embryon-
ic stem cell samples (HUES2) used in our study, shows very 
similar results to the 14 iPS cell lines. A high degree of corre-
lation was found between MRM assay and both genomic as-
says, with Spearman's correlation coefficients ranging from 
0.6 to 0.9 (p < 0.00001), with the highest correlation observed 
for OCT4. Proteomic levels were additionally compared to the 
classification results of both gene-expression based tests (Fig-
ure 2D). One of two iPSCs samples classified as borderline by 
ScoreCard shows consistently lower proteomic measurements 
outside the inter-quartile range for all four self-renewal mak-
ers. On the other hand, the single borderline iPSCs sample by 
PluriTest shows consistently higher proteomic levels outside 
the inter-quartile range, providing evidence for classifying this 
 sample as pluripotent by the MRM assay. Also, the 14d EBs 
classified as positive by ScoreCard (n=2) and PluriTest (n=4) 
show increased readouts of proteomic levels.  
Note that two more biomarkers (NANOG and c-MYC) that 
were included in the initial MRM assay design were moni-
tored by ScoreCard and PluriTest. Although NANOG was 
measured as differentially expressed between iPSCs and fi-
broblasts based on microarray and qPCR data, protein abun-
dance was only detected in one iPSC sample. A potential rea-
son for this could be due to the characteristic primary se-
quence of NANOG, containing tryptic cleavage sites cluster-
ing together in the center of the protein, therefore, decreasing 
number of potential peptides, which could be used in MRM 
assay. Additionally, NANOG has 11 phosphorylation sites 
(27) that could hinder the utility of modified peptides for 
MRM assay. Heavy phosphorylation results in the net negative 
charge of large regions of the protein, hampering the digestion 
efficiency of trypsin, which recognizes regions of net positive 
charge. Together this leads to tryptic fragments being too large 
and having poor propensity for ionization, thus hindering de-
tection of these peptides. c-MYC, for which protein levels 
were detected in half of the iPSCs samples, showed no signifi-
cant difference between iPSCs and fibroblasts, which was also 
observed for the gene expression data. 
Additionally, the accuracy of the MRM test in assessing the 
pluripotency signature was confirmed by submission of 7 
samples to a blind test (Table S-4). All iPSCs and fibroblast 
cell lines were properly classified into one of these groups 
(Figure 3). Interestingly, one sample expressed the OCT4, 
SOX-2, PODXL and LIN28 within the iPSCs range, but CD44 
was found to be close to the lower limit of the fibroblast range. 
Metadata revealed that this iPSCs sample differentiated spon-
taneously during cell culture, leading to the mixed expression 
of biomarkers. 
Logistic regression was used to obtain a classifier that can 
predict pluripotent versus non-pluripotent class assignment 
(data not shown). The MRM values of the five discriminative 
biomarkers for iPSC samples positively evaluated by Score-
Card (including HUES2 and excluding borderline samples; 
n=13) for self-renewal and the fibroblasts (negatively evaluat-
ed by ScoreCard; n=4) were used as training data. The seven 
blind samples were then used to evaluate the performance of 
the classifier. However, the training set represents a perfectly 
separable dataset, which is also true by using individual bi-
omarkers as a single predictor variable, resulting in perfect 
classification accuracy and preventing the estimation of re-
gression parameters. 
 
CONCLUSION 
Our targeted proteomic and mass-spectral based test demon-
strates that the measurement of the expression of proteins 
OCT4, SOX-2, LIN28, PODXL and CD44 can be successfully 
applied to assess the self-renewal potential of reprogrammed 
cells. The pluripotency signature measured by the mass spec-
trometry was confirmed by the generation of three-germ layer 
embryonic bodies and the successful terminal differentiation 
of these clones into neuronal cells (13, Hanseler et al., Mel-
guzo et al. in preparation).  
Due to the novel nature of our MRM-based test, we could 
not exploit publicly available transcriptional profiles of iPSCs 
from different laboratories, as it was done for the evaluation of 
genomic-based tests (11). To overcome this problem, we re-
programmed 14 new cell lines and submitted them to the pro-
teomic and two genomic tests. The comparison of MRM-
based results with TaqMan® hPSC ScoreCard™ Assay and 
PluriTest performed on the same cell lines has shown a high 
correlation between results based on transcriptomic and prote-
omic data, and allowed for the validation of our proteomic 
approach for measuring pluripotency signature. In all analyses, 
the targeted proteomic assay agreed with both genomic-based 
tests. The overall goal of our study was to generate a stream-
lined, economic and faster way to validate pluripotency of 
iPSCs, without compromising on the reliability of the assay. 
The main advantage of a targeted proteomic test is the low 
cost, high-throughput format and requirement of only 200,000 
cells for analysis. The sample digestion and purification can be 
performed in 96-well plates thus significantly increasing the 
speed of sample preparation. The results can be obtained with-
in only one day, including sample preparation, mass-
spectrometry analysis and data interpretation. To compare, 
ScoreCard and PluriTest assays require about 1 week to be 
performed, including sample preparation. Moreover, we esti-
mate the cost price of the targeted proteomic approach to be 
less than $20 per sample (assuming access to a mass spec-
trometer), which is significantly lower compared to the tran-
scriptomic approach, where the average price per sample is 
$150 for PluriTest and $175 for ScoreCard (17) (Figure S-4). 
The development of our new MS-based test is even more im-
portant in light of the announcement of Illumina to discontinue 
the HumanHT-12 v4 Expression BeadChip Kit by the end of 
2016. This will hamper access to the PluriTest assay, which is 
built upon this type of gene expression array. 
Our test can be implemented in any laboratory, which has 
access and expertise in using triple quadrupole mass spec-
trometers. Although targeted mass spectrometry approach has 
been already successfully applied in both biology and medi-
cine (28–30), the proteomics of iPSCs is still an emerging 
field, with the main interest in deep profiling of cells (31–34). 
Here we report for the first time the application of targeted 
proteomics to measure the pluripotency of iPSCs, which can 
potentially be translated into a diagnostic test. 
In the current design, this mass-spectral based test allows 
for assessment of self-renewal potential. However, it does not 
provide information about the differentiation efficiency into 
three germ layers as ScoreCard does, but this improvement is 
currently under development.  
In summary, we have developed a high throughput, rapid 
and cost-effective assay capable of directly measuring core 
pluripotency biomarkers used to assess pluripotency potential. 
This assay is significantly simpler and faster than conventional 
genomic tests. 
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